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Abstract.
Background: Macular pigment (MP) levels correlate with brain concentrations of lutein (L) and zeaxanthin (Z), and have also
been shown to correlate with cognitive performance in the young and elderly.
Objective: To investigate the relationship between MP, serum concentrations of L and Z, and cognitive function in subjects free
of retinal disease with low MP (Group 1, n = 105) and in subjects with AMD (Group 2, n = 121).
Methods: MP was measured using customized heterochromatic flicker photometry and dual-wavelength autofluorescence;
cognitive function was assessed using a battery of validated cognition tests; serum L and Z concentrations were determined by
HPLC.
Results: Significant correlations were evident between MP and various measures of cognitive function in both groups (r = –0.273
to 0.261, p ≤ 0.05, for all). Both serum L and Z concentrations correlated significantly (r = 0.187, p ≤ 0.05 and r = 0.197,
p ≤ 0.05, respectively) with semantic (animal) fluency cognitive scores in Group 2 (the AMD study group), while serum L
concentrations also correlated significantly with Verbal Recognition Memory learning slope scores in the AMD study group
(r = 0.200, p = 0.031). Most of the correlations with MP, but not serum L or Z, remained significant after controlling for age,
gender, diet, and education level.
Conclusion: MP offers potential as a non-invasive clinical biomarker of cognitive health, and appears more successful in this
role than serum concentrations of L or Z.
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INTRODUCTION
Carotenoids are a group of plant pigments which
are responsible for the bright color of a variety of
foods in nature. They are lipid soluble and divided
into oxygenated xanthophylls, and non-oxygenated
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(hydrocarbon) carotenes [1]. The macula, which is the
central part of the retina, is responsible for fine detailed
vision. Of interest, this specialized part of the retina
specifically accumulates the xanthophyll carotenoids
lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ)
(in a ratio of 1:1:1), where they are collectively referred
to as macular pigment (MP) [2]. The fact that the mac-
ula selects these three carotenoids from the more than
30 carotenoids available in human blood [3] suggests
that L, Z, and MZ have a specific role to play at this
tissue [4].
Indeed, it has been shown that MP’s constituent
carotenoids can prevent against oxidative damage to
the macula caused by reactive oxygen species, due to
the antioxidant nature of their polyene chains, which
actively quench these unstable molecules [5–7]. Also,
the optical properties of MP reduce the production of
reactive oxygen species at the macula, by absorbing
short wavelength (blue) light before it is incident on
the macula [8]. Importantly, the antioxidant and light
filtering properties of MP confer protection against
age-related macular degeneration (AMD), which is a
disease of the macula caused (at least in part) by cumu-
lative photo-oxidative injury, and is the most common
cause of blindness in the Western world [9, 10].
Research to date has demonstrated the importance of
MP for protecting against AMD progression [11–14],
and has also established that MP plays an important
role in enhancing visual function in both diseased
[15–19] and non-diseased [20] eyes, via the opti-
cal (light-filtering) properties of this pigment [21,
22]. Of note, it has been shown that supplementa-
tion [23–26], and in particular supplementation with
all three carotenoids (MZ, L, and Z) in a mg ratio of
10:10:2 may offer the best means of enriching MP
across its spatial profile [27–29], and impacts posi-
tively on visual function (e.g., contrast sensitivity and
glare disability) in human subjects [20].
Recent research has identified that L and Z are
also present in brain tissue, specifically the cerebel-
lum, pons, and the frontal/occipital cortices [30, 31].
L and Z were also detected in the hippocampus and
prefrontal and auditory cortices of human brain tissue
[32]. Interestingly, it has been found that MP levels
correlate with concentrations of L and Z (particularly
L) in the primate brain [31]. This had led researchers to
speculate that the macular carotenoids may also have
an antioxidant role in the brain, similar to that in the
human retina (the retina is part of the central nervous
system). Possible functions of carotenoids in the brain
include: antioxidant; anti-inflammatory; structural and
functional enhancement of synaptic membranes and
gap junction communication, and thereby may ulti-
mately protect against insult to cognition [33, 34].
Recent work by our group has shown that patients with
mild to moderate Alzheimer’s disease (AD) exhibit
significantly less MP, poorer vision, and a higher occur-
rence of AMD when compared to control subjects [19].
Moreover, in a subsequent clinical trial, we found that
supplementation with the macular carotenoids (MZ,
Z, and L) benefited patients with AD, in terms of
increases in MP and in terms of clinically meaning-
ful improvements in visual function [35]. In another
example, Rinaldi et al. have shown that in patients
with AD, plasma concentrations of L and Z were lower
in comparison to control subjects, with a significant
and inverse relationship observed between L concen-
trations and dementia severity [36, 37]. In another
study, supplemental L resulted in improved perfor-
mance in a range of cognitive tests in unimpaired
older women [38]. Indeed, it has been shown that
a positive relationship exists between MP levels and
cognitive performance in unimpaired and mildly cog-
nitively impaired adults [39–41]. Recent work has also
shown that MP levels are significantly related to better
global cognition, verbal learning and fluency, recall,
and processing and perceptual speed, whereas serum
L and Z levels were only significantly related to verbal
fluency in older adults with normal cognitive function
[42]. Taken together, these studies suggest that MP’s
constituent carotenoids may play a role in cognitive
function, and given the relationship between MP and
brain carotenoid levels, it is reasonable to hypothesize
that MP could be used as a biomarker for cognitive
function and/or AD; however, additional study in this
area is needed.
In this cross sectional baseline study, we report on
cognition and its relationship with MP and serum con-
centrations of its carotenoids in subjects free of retinal
disease with low MP (Group 1) and subjects with AMD
(Group 2) from the Central Retinal Enrichment Sup-
plementation Trials (CREST) study [43].
MATERIALS AND METHODS
CREST is a double blind, parallel group, and ran-
domized controlled clinical trial, which studies the
impact of macular carotenoids (L, Z, and MZ) on visual
function in two subject populations; normal subjects
with low MP (non-diseased) (Trial 1), and subjects
with early AMD (Trial 2). Clinical assessments were
conducted by the researchers J.D. (Trial 1) and K.O.A.
(Trial 2), who were suitably trained on all aspects of the
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CREST protocol. The methods for the CREST clini-
cal trial have been previously described in detail [43].
The primary outcome measure in both trials is Contrast
Sensitivity (CS) at 6 cycles per degree, while secondary
outcome measures include CS at other spatial frequen-
cies, glare disability, visual acuity, light scatter, photo
stress recovery, foveal architecture, subjective visual
function, serum carotenoid concentrations, MP, and
cognitive function. Reading acuity, reading speed, and
AMD morphology are also assessed in Trial 2.
Subjects
Recruitment for Trial 1 involved organized national
and local advertising campaigns, including in Irish
newspapers, on radio stations and through online
adverts. Flyers were also distributed to the general
public. In addition, educational events were held for
optometrists, ophthalmologists, and general practition-
ers, which created awareness of the trial, and aided
in recruitment. Following the recruitment campaign,
interested subjects attended our Vision Research Cen-
tre to undergo an initial assessment which determined
if they met the eligibility criteria for inclusion.
Inclusion criteria for Trial 1 (Group 1) included: (1)
≥18 years; (2) best-corrected visual acuity (BCVA) of
6/6 or better; (3) no more than five diopters spherical
equivalence of refraction; (4) no previous consumption
of supplements containing L, Z, and/or MZ; (5) no ocu-
lar pathology; and (6) MP at 0.25 degrees eccentricity
of less than 0.5 optical density units.
Subjects recruited into Group 1 were those who
exhibited no abnormalities in their vision following a
range of tests including BCVA, fundus photography,
optical coherence tomography (OCT), and comple-
tion of a general health questionnaire, all under the
supervision of a retinal specialist. Thus, this group
of subjects were adjudged “normal” in every respect,
except that their central MP levels were below-average.
Low MP, for purposes of selecting Group 1 study sub-
jects, was defined as 0.5 optical density units or below
at 0.25 degrees eccentricity; 85% of Group 1 sub-
jects were below this level, 95% were below 0.58, and
none exceeded 0.7 units. The reasons for recruiting
this Low MP group are detailed as follows: 1) Subjects
with Low MP may have a higher tendency to exhibit
beneficial effects following supplementation because
of the higher likelihood for an increase in MP lev-
els; 2) Subjects recruited in Group 1 had visual acuity
of at least 6/6 and therefore typically exhibit ceiling
effects on visual function tests. The impact of MP aug-
mentation on visual function may be more evident in
the low MP group given that these subjects have a
wider range of possible/probable MP increase; 3) The
Group 1 subjects may have certain genetic/lifestyle
characteristics which preclude efficient absorption of
the macular carotenoids at the macula; 4) One of the
recommendations from the Collaborative Optical Mac-
ular Pigment Assessment Study (COMPASS) [44] was
that further studies on the impact of MP augmenta-
tion on visual function should focus on individuals
with low MP and therefore the current study was
designed to fill this gap in the scientific literature;
5) Interestingly, in the AREDS2 study [11], benefi-
cial effects of MP’s constituent carotenoids in terms
of visual function and progression to advanced AMD
were demonstrated more in subjects with low dietary
intake of these carotenoids (and perhaps low MP group
given that L, Z, and MZ are not synthesized de novo
and can only be obtained through the diet and sup-
plements). Of note, this is the first clinical trial to
specifically recruit subjects with Low MP.
Recruitment for Trial 2 was carried out with the help
of eye centers, who were used to raise awareness of the
trial. As for Trial 1 above, educational events were held
for optometrists, ophthalmologists, and general practi-
tioners, which created awareness of the trial, and aided
in recruitment. Interested and potentially suitable sub-
jects attended our vision research center for a screening
examination with an emphasis on the presence of early
AMD. This was carried out by a consultant ophthal-
mologist with a special interest in AMD (SB). Subjects
who were deemed suitable for the trial following this
screening visit had stereo fundus photographs taken,
which were then sent to the Reading Centre at Moor-
fields Eye Hospital, London for confirmation of the
presence of early AMD in subject eyes. These subjects
were then invited to participate in Trial 2.
Inclusion criteria for Trial 2 (Group 2) included: 1)
BCVA of 6/12 or better; 2) no more than five diopters
spherical equivalence of refraction; 3) no previous con-
sumption of supplements containing L, Z, and/or MZ;
4) no retinal pathology beyond AMD; and 5) no dia-
betes mellitus.
Subjects were included in the early AMD category
(Group 2) if early AMD was seen in at least one eye
based on the grading of a fundus photograph from one
to eight [43] on the Age Related Eye Disease Study
(AREDS) 11-step severity scale [45].
Demographic variables
A demographic and lifestyle questionnaire was pro-
vided to all subjects, which obtained details on: address
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and contact number, education level, occupation, eth-
nicity, smoking habits (frequency and history), alcohol
intake (average weekly consumption and frequency),
dietary intake of L and Z using an L/Z screener
[19], exercise (sessions per week and duration), light
exposure (time spent outdoors, use of sunglasses,
photochromic lenses), body mass index (BMI)
(kg/m2), medical history, blood pressure, and ocular
medical history. For the purposes of this publication,
the following demographic and behavioral variables
were included in the analysis: age, gender, smoking
habits, diet score, exercise routine, education level,
alcohol intake, and BMI.
Ethical approval
All subjects provided written consent of their
willingness to enroll, and participate in, the CREST
trials. Ethical approval for the study was granted
by the Ethics Committee of the European Research
Council (ERC) and the Ethics Committee of the
Waterford Institute of Technology (WIT), Waterford,
Ireland. The trials also adhered to the tenets of the
Declaration of Helsinki, and followed the ethics code
with respect to subject recruitment, testing and data
protection.
Macular pigment measurement
MP levels were measured firstly by customized
heterochromatic flicker photometry (cHFP) using
the Macular Densitometer (Macular Metrics Corp,
Providence, RI, USA) [46, 47]. Briefly, MP’s spatial
profile was assessed by measuring MP at 0.25◦, 0.5◦,
1.0◦, and 1.75◦ of retinal eccentricity, with a reference
point located at 7◦. The HFP edge effect is assumed
in this study. Thus, the 0.25◦, 0.5◦, 1◦, 1.75◦, and
7◦ (the reference point) were obtained using the
target diameters: 30-min (0.5◦), 1◦, 2◦, 3.5◦, and 2◦,
respectively. For the 7◦ target, a 2◦ diameter disc
with its center located 7◦ from a red fixation point
was used.
A detailed description of this technique has been
presented previously [48, 49]. MP levels were also
measured by dual-wavelength autofluorescence using
the Spectralis HRA + OCT Multicolour (Heidelberg
Engineering GmbH, Heidelberg, Germany). This
method has been described in detail elsewhere [50–52].
MP at 0.25◦ and 0.5◦ eccentricities (Densitometer),
and total MP volume (Spectralis) are reported in
this study.
Serum carotenoid (L and Z) analysis
Non-fasting blood samples were collected from
study subjects in 9 mL vacuette tubes each containing
a “Z Serum Sep Clot Activator.” Collection tubes were
inverted at least five times to ensure thorough mixing
of the clot activator. The blood samples were then left
to clot for 30 min at room temperature, after which they
were centrifuged at 725 g for 10 min in a Gruppe GC 12
centrifuge to separate the serum from the whole blood.
Serum sections were then transferred to light-resistant
micro tubes and stored at –80◦C until further analysis
was necessary. Serum carotenoid measurements were
carried out as described previously [19].
Assessment of cognitive function
Cognition was assessed using various validated
measurements. Phonemic fluency (the FAS test) was
measured by completing as many words as possible,
starting with each letter, and allowing a 1-min time
limit per letter [47]. A semantic fluency score was also
examined using “Animal” as the chosen category, with
the subject required to give as many exemplars as possi-
ble in 1 min [47]. A battery of tests from the Cambridge
Neuropsychological Test Automated Battery [53, 54]
(CANTAB, Cambridge Cognition, Cambridge, UK)
were used to assess cognitive response in subjects
using a computerized software program. These tests
required a finger-operated subject response on a touch-
screen tablet PC. A set of scripted instructions was
provided for each test. The cognition tests were con-
ducted at near distance of approximately 30–40 cm
from the subject, and all subjects had near vision of
sufficient quality to conduct the cognition tests using
the CANTAB device. The actual tests used were as
follows: (i) A modified version of the Verbal Recogni-
tion Memory task (VRM) was selected to assess verbal
learning and memory [47, 48]. In the modified version
a free recall format was used instead of a recognition
format for the three learning trials, and subsequently
both delayed free recall and delayed recognition were
evaluated. In this task, the subject was asked to recall
as many words as possible after being presented with a
list of 12 words, one at a time. This was repeated three
times, with scores calculated for free recall for each
learning trial, total immediate free recall (sum of the
three learning trials), and number of intrusion errors
(recalling words that had not been presented). Under
the delayed free-recall condition, the subjects were
tested on their ability to complete a free recall phase
(number of words free recalled and number of intrusion
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errors). This was followed by a recognition phase in the
presence of a matched set of distractor words, and the
scores include the number of list words correctly rec-
ognized and the number of distractor words incorrectly
identified as list words (false positives); (ii) Attention
switching task (AST) [53, 55], which is a test of the
participant’s ability to switch attention between the
direction of an arrow and its location on the screen,
while ignoring irrelevant information from interfering
or distracting events. This test is designed to mea-
sure top-down cognitive control processes involving
the prefrontal cortex, and displays an arrow, which can
appear on either the right or left side of the screen
and can point in either direction. Each trial displays
a cue at the top of the screen that indicates whether
the subject should press the right or left button accord-
ing to the “side on which the arrow appeared” or the
“direction in which the arrow was pointing”. Some tri-
als also display congruent stimuli (e.g., arrow on the
right side of the screen pointing to the right) whereas
other trials display incongruent stimuli which require
higher cognitive skills (e.g., arrow on the right side
of the screen pointing to the left). AST outcome mea-
sures include response latencies and error scores that
reflect the participant’s attention switching ability and
the interference of incongruent task-irrelevant infor-
mation; (iii) the paired associate learning (PAL) [56],
a test which assesses visual memory and new learn-
ing. The subject is presented with a set of white boxes,
some of which contain a particular pattern, with the
subject being tasked with remembering the location
of each of the patterns. The difficulty of the test is
gradually increased, and if a mistake is made the sub-
ject is reminded of the pattern location and is given
another opportunity to select the correct box. The test
ends when the final stage is completed or if a subject
exceeds a specified number of attempts at any given
stage. The official CANTAB protocol was followed in
the administration of all tests [57].
Statistics
The statistical package IBM SPSS version 21 was
used for all analyses. The primary outcome measures
were baseline MP, serum L and Z concentrations, and
cognitive scores. Relationships among these variables
in subjects free of retinal disease with low MP (Group
1) and in subjects with early AMD (Group 2) were
first investigated using elementary methods, in partic-
ular, bivariate correlations and independent samples
t-tests. Statistically significant results, identified from
the bivariate analyses, were then re-analyzed using
general linear models, in order to control for possible
confounding variables (such as age, education level,
gender, and diet score). The 5% significance level was
used throughout all analyses, without adjustment for
multiple tests.
Initial examination of the data revealed a very lim-
ited range of values for some cognitive variables. This
was particularly true for some of the VRM cognitive
variables (e.g., VRM Trial 3 recall and VRM Trial 3
intrusion errors). We treated such variables as cate-
gorical rather than quantitative, combining adjacent
categories to form new “low” and “high” cognitive
score categories. Associations between these new vari-
ables, and quantitative variables such as MP, were then
analyzed using independent samples t-tests, and graph-
ically investigated using box-plots.
RESULTS
Table 1 presents the baseline demographic, health
and lifestyle, and MP data, while Table 2 presents the
cognition data in subjects free of retinal disease with
low MP (Group 1) and in subjects with early AMD
(Group 2) in the CREST trial. As presented in Table 1,
there were statistically significant differences between
the study groups in terms of age, diet, education level,
and gender, and hence we controlled for these where
appropriate in all subsequent analyses.
Relationship between macular pigment optical
density and cognitive scores
a. Subjects free of retinal disease with low MP
(Group 1)
Significant relationships between MP and cognitive
scores in the subjects free of retinal disease with low
MP (Group 1) are presented in Table 3 and in Figs. 1
and 2a and b.
As presented in Table 3, the following cognitive vari-
ables correlated negatively and significantly with MP
0.25◦: PAL Total Errors, PAL Total Errors at Stage 6,
and AST congruency cost; the negative correlations
here indicated that higher MP was associated with bet-
ter cognitive scores in this group. After controlling for
age, gender, diet, and education level, using a gen-
eral linear model, these relationships with MP 0.25◦
remained significant (p = 0.009 for PAL Total Errors,
p = 0.006 for PAL Total Errors at Stage 6, and p = 0.022
for AST congruency cost). In addition, and also as
presented in Table 3, the VRM learning slope vari-
able correlated positively and significantly with MP
0.25◦, indicating that higher MP was associated with
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Table 1
Demographic, health and lifestyle, and macular pigment data of the subjects free of retinal disease with low MP (Group 1) and subjects with
early AMD (Group 2)
Variables Low MP group AMD group Sig.
(n = 105) (n = 121)
Age (years) 47 ± 12.1 65 ± 9 <0.001
Body mass index (kg/m²) 26.6 ± 4.5 28.0 ± 4.5 0.020
Exercise (total exercise per week) 306.4 ± 309.5 346.5 ± 390.6 0.416
Diet score (Estimated lutein and zeaxanthin intake) 22.6 ± 13.5 26.2 ± 12.1 0.034
Serum lutein (mol/l) 0.245 ± 0.14 0.306 ± 0.20 0.01
Serum zeaxanthin (mol/l) 0.092 ± 0.06 0.105 ± 0.09 0.207
Education (highest level %) <0.001
Primary 1.9 14.9
Secondary 23.8 47.1
Higher (third level) 74.3 38
Smoking (%) 0.101
Never smoked 48.1 48.8
Past smoker 33.7 42.1
Current smoker 18.3 9.1
Alcohol (%) 0.155
Never drink 5.8 12.5
Drink on special occasions 13.5 20
Drink once or twice a month 22.1 19.2
Drink once or twice a week 52.9 39.2
Drink every day 5.8 8.3





MP 0.25 0.388 ± 0.11 0.751 ± 0.25 <0.001
MP 0.5 0.305 ± 0.12 0.626 ± 0.21 <0.001
MP volume 4189 ± 1758 5349 ± 2630 <0.001
Data displayed are mean ± standard deviation for numerical data and percentages for categorical data. Variables, variables analyzed in the study;
AMD group, subjects recruited into the study confirmed as having AMD in at least one eye; Low MP group, subjects recruited into the study
with MP at 0.25 degrees of eccentricity less than 0.5 optical density units; Sig., the statistical difference (p value) between AMD and low MP
subjects assessed using either independent samples t-tests or chi-squared depending on the variable of interest; Body mass index, Measure
of body fat based on height and weight; Exercise, total exercise measured as minutes per week engaged in physical or sporting activity; Diet
score, estimated dietary intake of lutein and zeaxanthin; Education, highest level to which subject was educated; Smoking, current smoker
(smoked ≥100 cigarettes in lifetime and at least one in the last year), past smoker (smoked ≥100 cigarettes in lifetime and none in past year), or
non-smoker (smoked < 100 cigarettes in lifetime); Alcohol, as above; MP 0.25, spatial profile of MP measured at 0.25◦ of retinal eccentricity,
with a reference point at 7◦ (measured using the macular densitometer); MP 0.5, spatial profile of MP measured at 0.5◦ of retinal eccentricity,
with a reference point at 7◦ (measured using the macular densitometer); MP volume, a volume of MP calculated as MP average times the area
under the curve out to 8◦ eccentricity (measured using the Heidelberg Spectralis®).
better cognitive scores. The relationship between MP
0.25 and VRM learning slope was, however, no longer
statistically significant (p = 0.273) after controlling for
age, gender, diet, and education level.
Two cognitive variables in Table 3 were significantly
related to MP 0.5◦: the first, a negative correlation with
PAL Total Errors at Stage 6. Of note, again, the negative
correlation indicates that higher MP was associated
with better cognitive scores in this group. After con-
trolling for the same demographic variables mentioned
above (age, gender, diet, and education level), this cor-
relation remained statistically significant (p = 0.004).
The second variable which was significantly related
to MP 0.5◦ was the VRM learning slope variable. The
positive correlation here indicated that higher cogni-
tive scores were seen in patients with higher MP levels.
The significant relationship between MP 0.5◦ and
VRM learning slope no longer persisted (p = 0.378)
after controlling for age, gender, diet, and education
level.
As illustrated in the boxplots in Fig. 2a and b, higher
MPvaluesat0.25◦ and0.5◦ wereassociatedwithhigher
memoryscores,andhencebettercognitiveperformance
for VRM Trial 3 recall (p = 0.014 and p = 0.032, respec-
tively). The relationships between MP 0.25◦ and 0.5◦
and VRM Trial 3 recall were no longer significant after
controlling for age, gender, diet. and education level
(p = 0.360 and p = 0.570, respectively).
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Table 2
Cognition data of the subjects free of retinal disease with low MP (Group 1) and subjects with early AMD (Group 2)
Variables Low MP group AMD group Sig.
(n = 105) (n = 121)
FAS test 42.4 ± 13.5 34.1 ± 12.7 <0.001
Animal fluency 21.6 ± 5.8 15.5 ± 4.0 <0.001
VRM Trial 1 recall 8.2 ± 1.8 5.0 ± 1.6 <0.001
VRM Trial 2 recall 9.9 ± 1.5 8.6 ± 1.9 <0.001
VRM Trial 3 recall 10.5 ± 1.9 9.7 ± 1.6 0.002
VRM total immediate free recall 28.6 ± 4.3 23.4 ± 4.2 <0.001
VRM learning slope 2.3 ± 2.0 4.7 ± 1.8 <0.001
VRM Trial 1 intrusion errors 0.09 ± 0.35 0.17 ± 0.45 0.159
VRM Trial 2 intrusion errors 0.08 ± 0.31 0.10 ± 0.33 0.641
VRM Trial 3 intrusion errors 0.02 ± 0.20 0.04 ± 0.24 0.471
VRM Delayed Free Recall 9.4 ± 2.5 7.6 ± 2.4 <0.001
VRM Delayed Free Recall intrusion errors 0.09 ± 0.32 0.2 ± 0.5 0.025
VRM Delayed Recognition total 23.3 ± 3.5 23.1 ± 1.5 0.468
VRM Delayed Recognition false positives 0.09 ± 0.32 0.2 ± 0.5 0.038
AST Mean Correct Latency 836.6 ± 197.9 1068.2 ± 198.5 <0.001
AST Congruency Cost 108.7 ± 98.8 168.7 ± 120.8 <0.001
AST Switch Cost –117.8 ± 114.2 –101.0 ± 140.3 0.334
AST Percent Correct 94.3 ± 6.4 82.8 ± 16.2 <0.001
PAL Total Errors 19.6 ± 23.2 49.0 ± 33.1 <0.001
PAL Total Errors at Stage 6 5.8 ± 6.4 12.6 ± 10.1 <0.001
PAL Memory score 19.5 ± 5.3 13.3 ± 5.1 <0.001
Data displayed are mean ± standard deviation for numerical data. Variables, variables analyzed in the study; FAS, a phonemic fluency score
generated by the total number of words produced for each of the letters F, A, and S in 1 min (high score is preferable); Animal fluency, (semantic
fluency score) a semantic fluency score obtained from the number of animals named by the subject in 1 min (high score is preferable); VRM
(Verbal Recognition Memory) Trial 1, 2, and 3 recall and total immediate free recall. Subject is asked to recall as many words as possible after
being presented with a list of stimuli. This is repeated three times and scores are calculated for each individual trial in addition to a total score,
(high score is preferable); VRM learning slope, trial 3 recall – trial 1 recall (high score is preferable); VRM Trial 1, 2, and 3 intrusion errors,
number of words recalled that did not appear in the list (low score is preferable); VRM Delayed free recall, number of list words free recalled
after a delay (high score is preferable); VRM Delayed free recall intrusion errors, number of words recalled after a delay that did not appear in
the list (low score is preferable); VRM Delayed Recognition total, recognition memory of the previous words after a delay period. Subjects are
tested on their ability to complete a recognition phase in the presence of a matched set of distractor stimuli and are scored on the total number of
correctly identified list words and distractors (high score is preferable); VRM Delayed Recognition false positives, the total number of times that
the subject responds “yes” incorrectly to a distractor word (low score is preferable); AST Mean Correct Latency, Attention Switching Task, the
algorithm of the latency of response from stimulus appearance to button press. It is a test of the participant’s ability to switch attention between
the direction of an arrow and its location on the screen, while ignoring irrelevant information from interfering or distracting events (low score is
preferable); AST Congruency Cost, the difference between the algorithm response latency from stimulus appearance to button press of congruent
versus incongruent assessed trials. It is calculated by subtracting the algorithm response latency for congruent trials from the algorithm reaction
latency for incongruent trials (a positive score indicates that the subject is faster on congruent trials and a negative score indicates that the
subject is faster on incongruent trials) Congruent trial = Trial where the arrow was on the same side as the direction it was pointing. Incongruent
trial = Trial where the arrow was on one side but pointing in the opposite direction; AST Switch Cost, The difference between the algorithm
response latency from stimulus appearance to button press of non-switched versus switched assessed trials. It is calculated by subtracting the
algorithm response latency for non-switched trials from the algorithm reaction latency for switched trials. Switched trials = trials where the
trial type was Side but the previous trial type was Direction, or the trial type was Direction but the previous trial type was Side. Non-switched
trials = trials where the trial type was the same as the previous trial. A positive score indicates that the subject is faster on non-switched trials,
and a negative score indicates that the subject is faster on switched trials. AST Percent Correct, percentage of trials, as filtered by the parameters
set using available options, for which the trial outcome was a correct response (high score is preferable); PAL Total Errors, Paired Associates
Learning (total errors adjusted) measures visual memory and new learning of subjects by assessing the total number of errors across all assessed
problems and stages, with an adjustment for each stage not attempted due to previous failure (low score is preferable); PAL Total Errors at Stage
6, Paired Associates Learning (total errors adjusted at the 6 pattern stage) measures the total number of errors made at the 6-pattern stage (when
there is a stimulus in each of 6 boxes), with an adjustment for those who have not reached this stage (low score is preferable); PAL Memory
score (first trial memory score), the number of patterns correctly located after the first trial, summed across the stages completed (high score
is preferable).
b. Subjects with early AMD (Group 2)
Significant relationships between MP and cognitive
scores in the AMD study group (Group 2) are presented
in Table 3, Figs. 2c, and 3.
As seen in Table 3, the following cognitive variables
correlated significantly with MP 0.25◦: FAS test, ani-
mal fluency, AST percent correct, PAL Total Errors,
and PAL Total Errors at Stage 6. The correlations with
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Table 3
Significant correlations between MP and cognitive scores in subjects free of retinal disease with low MP (Group 1) and subjects with early AMD
(Group 2)
Low MP group AMD group
Densitometer Spectralis Densitometer Spectralis
MP 0.25 MP 0.5 AF MP vol. MP 0.25 MP 0.5 AF MP vol.
Cognitive test r value p value r value p value r value p value r value p value r value p value r value p value
FAS test 0.072 0.476 0.116 0.248 0.002 0.982 0.261 0.004 0.244 0.008 0.160 0.083
Animal fluency 0.008 0.933 0.000 0.997 0.003 0.975 0.186 0.044 0.188 0.042 0.171 0.063
AST Congruency Cost –0.201 0.045 –0.103 0.308 –0.063 0.530 0.122 0.188 0.127 0.173 0.091 0.325
AST Percent Correct 0.004 0.971 –0.004 0.972 0.091 0.364 0.214 0.020 0.200 0.030 0.111 0.230
PAL Total Errors –0.247 0.013 –0.184 0.067 0.128 0.204 –0.224 0.015 –0.180 0.052 –0.030 0.744
PAL Total Errors Stage 6 –0.273 0.006 –0.235 0.018 0.181 0.071 –0.183 0.047 –0.145 0.117 –0.050 0.586
VRM Learning Slope 0.258 0.009 0.290 0.003 0.005 0.959 –0.079 0.397 –0.046 0.617 –0.025 0.786
MP, macular pigment; AMD group, subjects recruited into the study confirmed as having early AMD in at least one eye; Low MP group, subjects
recruited into the study with MP at 0.25 degrees of eccentricity less than 0.5 optical density units; Densitometer, measures MPOD at 0.25 and
0.5 degrees of eccentricity by customized heterochromatic flicker photometry; Spectralis, measures MP volume, a volume of MP calculated as
MP average times the area under the curve out to 8 degrees eccentricity. r value, Pearson’s correlation coefficient, is a measure of the strength
of the association between the two variables; p value, the statistical significance of the correlation between two variables, with correlations
considered statistically significant when p = <0.05; FAS test, a word fluency score generated by the total number of words produced for each
of the letters F, A, and S in 1 minute (high score is preferable); Animal fluency, (semantic fluency score) a semantic fluency score obtained
from the number of animals named by the subject in 1 minute (high score is preferable); AST Congruency Cost, Attention Switching Task, the
difference between the algorithm response latency from stimulus appearance to button press of congruent versus incongruent assessed trials.
It is calculated by subtracting the algorithm response latency for congruent trials from the algorithm reaction latency for incongruent trials (a
positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials);
AST Percent Correct, Attention Switching Task, percentage of trials, as filtered by the parameters set using available options, for which the trial
outcome was a correct response (high score is preferable); PAL Total Errors, Paired Associates Learning (total errors adjusted) measures visual
memory and new learning of subjects by assessing the total number of errors across all assessed problems and stages, with an adjustment for
each stage not attempted due to previous failure (low score is preferable); PAL Total Errors at Stage 6, Paired Associates Learning (total errors
adjusted at the 6 pattern stage) measures the total number of errors made at the 6-pattern stage (when there is a stimulus in each of 6 boxes),
with an adjustment for those who have not reached this stage (low score is preferable); VRM learning slope, trial 3 recall – trial 1 recall (high
score is preferable); p values which are significant at the 5% level are highlighted in bold.
Fig. 1. Relationships between macular pigment optical density and cognitive scores in subjects free of retinal disease with low MP (Group 1).
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Fig. 2. Boxplots of macular pigment optical density (MPOD 0.25◦, 0.5◦, and MP volume) and its relationship to Verbal Recognition Memory
(VRM) scores in subjects free of retinal disease with low MP (Group 1) and in subjects with early AMD (Group 2).
MP 0.25◦ were positive for FAS test, animal fluency,
and AST scores, and negative for both PAL scores.
Thus, for each of these tests, higher MP was associ-
ated with better cognitive scores. Controlling for age,
education level, gender, and diet, using a general lin-
ear model, these relationships with MP 0.25◦ remained
significant or nearly significant for the majority of
the tests (p = 0.050 for FAS test, p = 0.040 for AST
percent correct, p = 0.039 for PAL Total Errors, and
p = 0.095 for PAL Total Errors at Stage 6) but the rela-
tionship with animal fluency was no longer significant
(p = 0.776).
Three cognitive variables in Table 3 correlated sig-
nificantly with MP 0.5◦: FAS test, animal fluency,
and AST percent correct; these correlations were pos-
itive, indicating that higher MP 0.5◦ was associated
with better cognitive scores. Controlling for age, edu-
cation level, gender, and diet, using a general linear
model, these relationships with MP 0.5◦ remained
significant or nearly significant (p = 0.067 for FAS
test, p = 0.030 for AST percent correct), while the
relationship with animal fluency was no longer sig-
nificant (p = 0.386).
As illustrated in the boxplot in Fig. 2c, higher MP
volume was associated with lower recall errors, and
hence better cognitive performance for VRM Trial 3
intrusion errors (p = 0.016). This relationship remained
statistically significant (p = 0.008) after controlling for
age, gender, diet, and education level.
Relationship between serum L concentration and
cognitive scores
We found two statistically significant relationships
between serum L concentrations and cognitive scores,
and both were found in the AMD study group
(Group 2). The cognitive test scores which corre-
lated with serum L concentrations were animal fluency
(p = 0.047) and VRM learning slope (p = 0.031); see
Fig. 4a and b. The correlations were positive, indicating
that higher serum L is associated with better cogni-
tive performance. The relationships between serum L
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concentration and animal fluency (p = 0.699) and VRM
learning slope (p = 0.254) were no longer statistically
significant, after controlling for age, education level,
gender, and diet.
Relationship between serum Z concentration and
cognitive scores
We found only one statistically significant relation-
ship (p = 0.046) between serum Z concentrations and
cognitive scores, and it was again only noted in the
AMD study group (Group 2) and for the animal fluency
cognitive test; see Fig. 4c. The correlation was posi-
tive, indicating that higher serum Z is associated with
better cognitive performance. However, the correlation
between serum Z and animal fluency was no longer
statistically significant (p = 0.773), after controlling for
age, education level, gender, and diet.
Relationship between macular pigment optical
density and serum L and Z concentrations
a. Subjects free of retinal disease with low MP
(Group 1)
Serum L concentrations correlated significantly
with all measures of MP (MP 0.25◦, MP 0.5◦, AF
MP volume) in this group (p = 0.030, 0.024, <0.001
respectively), while serum Z concentrations corre-
lated significantly with MP volume (p = <0.001). These
significant relationships (between L, Z, and MP) all
remained after controlling for age, gender, education
level, and diet, in this study group.
b. Subjects with early AMD (Group 2)
Serum L concentrations correlated significantly with
all measures of MP (MP 0.25◦, MP 0.5◦, AF MP
volume) in the AMD study group (p = 0.034, 0.023,
<0.001). Serum Z concentrations also correlated sig-
nificantly, in this study group, with MP volume
(p = 0.003). Controlling for age, gender, education
level, and diet in the AMD study group, however, MP
at 0.25◦ (p = 0.356) and 0.5◦ (p = 0.215) were no longer
significantly correlated with serum L concentrations.
The significant correlation between MP volume and
serum Z became borderline (p = 0.067).
DISCUSSION
This study presents findings on the respective rela-
tionships between cognitive function, MP, and serum
concentrations of its constituent carotenoids, in sub-
jects free of retinal disease with low MP (Group 1) and
in subjects with early AMD (Group 2), all of whom
are participants in CREST (a clinical trial designed
to study the impact of carotenoid supplementation on
vision in patients with AMD and in subjects free of
retinal disease with low MP at baseline) [43]. The ratio-
nale and motivation for performing the current study
relates to the possible role that these carotenoids play in
brain health and function. Indeed, in what is becoming
an emerging area of scientific research, several recent
reviews have discussed the link between the macular
carotenoids and cognitive performance [33, 34, 58, 59],
and we know that L and Z are found in the human brain
[30, 32, 60]. In addition, in non-human primates, it has
been shown that carotenoid concentrations in the retina
correlate with brain concentrations of these nutrients
[61], and that serum concentrations of L and Z corre-
late with brain carotenoid levels in elderly adults [60].
Moreover, several studies have demonstrated a link
between MP and cognitive performance [39–42], and
our group has shown that subjects with moderate AD
have significantly lower MP when compared to control
subjects [19], and, in addition, a follow on study has
demonstrated that supplementation with the macular
carotenoids significantly increases serum concentra-
tions of L and Z and MP levels in these subjects [35].
However, the current investigation is the first report on
the respective relationships between MP (and serum
concentrations of its constituent carotenoids), and cog-
nitive function in subjects free of retinal disease with
low MP (Group 1) and in subjects with early AMD
(Group 2).
The main finding from this work was that significant
correlations exist between MP and cognitive scores in
each study group. For example, higher MP levels were
associated with better performance in several cogni-
tive tests, including: 1) phonemic fluency, which is
primarily dependent on frontal cortex integrity [62];
2) attention switching, which reflects prefrontal cortex
functioning in top down cognitive control processing
[63]; 3) visual and verbal memory and learning [64, 65]
which involve a variety of brain regions, including
anterior medial regions of the prefrontal cortex, lat-
eral parietal/temporal regions, the medial region of the
posterior cingulate, and the hippocampus [66].
Of note, our findings are consistent with reports of
other investigators; for example, previous work has
shown that MP is significantly related to visual - motor
performance, i.e., the link between the visual (eye)
cue and motor (brain) response of the central nervous
system in both older and younger subjects [40, 67].
Moreover, a recent publication found a link between
MP and cognitive function in older adults [41]. In
that study, where they tested healthy subjects, MP
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Fig. 3. Relationships between macular pigment optical density and cognitive scores in subjects with early AMD (Group 2).
levels were only related to visual-spatial and construc-
tional abilities, while for subjects with mild cognitive
impairment, MP levels correlated with a broad range
of cognitive measures including visual-spatial and
constructional abilities, attention, language ability, and
both immediate and delayed memory [41]. A similar
finding was also reported in a recent study where MP
levels were significantly related to processing speed,
recall, verbal learning and fluency, perceptual speed,
and better global cognition in a group of older subjects
[42]. In addition, a large study in a group of older adults
found that lower MP correlated with poor performance
on a range of cognitive tests examining executive
function, processing speed, prospective memory, and
reaction times [39]. Finally, our group has shown that
subjects with moderate AD have significantly lower
MP when compared to control subjects [19]. Also,
and interestingly, in the non-interventional phase of a
recent study involving young healthy subjects, a mod-
erate, yet significant, correlation was found between
MP and visual processing and neural efficiency,
indicating that the relationship between MP and cog-
nitive function is not only present in older populations
[67]. In summary, our findings are consistent with these
studies, in that similar relationships were seen between
MP and cognitive function in both younger (i.e., in
subjects free of retinal disease with low MP [Group
1]) and in older subjects (with early AMD [Group 2]).
Of importance, our finding that MP is correlated with
cognitive performance on tasks with a prominent exec-
utive functioning component dependent on the frontal
cortex [68, 69] is interesting, given that L and Z are
known to be present in high concentrations in this area
of the brain [30].
Of note, MP is considered a stable measure of tis-
sue L + Z concentrations and is representative of
long term carotenoid intake, as opposed to serum con-
centrations, which reflect more recent dietary activity
[42, 70]. Accordingly, it is reasonable to suggest that
MP levels in the retina are representative of L and Z
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Fig. 4. Relationships between serum concentrations of lutein (L) and zeaxanthin (Z) (mol/l) and cognitive scores in subjects with early AMD
(group 2).
concentrations in the brain, given that this relationship
has been demonstrated in non-human primates [71]
(L and Z in the retina correlated with L and Z in the
cerebellum and to a lesser extent in the occipital cor-
tex, while Z concentrations in the retina correlated with
those in the pons and frontal cortex of the brain in rhe-
sus monkeys). Since correlations between MP levels
and cognition in the human brain [72] have also been
demonstrated, the possibility that MP may be used as a
biomarker for brain concentrations of the carotenoids
and, therefore, by extension, cognition, is plausible and
provocative.
Previous studies have also shown that serum L and
Z concentrations are related to cognitive function in
older adults [60, 73, 74], and that serum L and Z lev-
els are depleted in subjects with MCI [36] and with
AD [75, 76]. However, some cognitive scores, such as
verbal fluency, are known to be related also to age and
education [36] and these variables, in turn, are related
to diet. Of note, there is also evidence that L and Z
serum concentrations are related to age, education, and
diet [77–79]. With respect to the relationship between
serum carotenoids and cognitive function in our study,
we found few significant correlations. Indeed, and
only for the AMD subjects (Group 2), serum L and
Z concentrations correlated significantly with seman-
tic (animal) fluency cognitive scores, a task that relies
predominantly on temporal lobe functioning [62], and
this observation is consistent with the work of others
[42], while serum L concentrations also correlated sig-
nificantly with VRM learning slope scores in the same
group, this test indicating the learning ability of the
subjects [66]. However, in contrast to our findings for
MP, relationships between these cognitive scores and
serum L or Z, were not statistically significant when
we controlled for age, education, and diet.
This, in conjunction with the paucity of relation-
ships, in our study, between serum concentrations of
L and Z and the remaining cognitive tests, given the
many relationships observed between MP and the same
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cognitive tests, suggests that retinal tissue concentra-
tions of these antioxidants represent a more valid and
valuable biomarker of brain concentrations of these
carotenoids than their respective serum levels. Indeed,
this superior suitability of retinal tissue concentrations
was suggested in a recent letter by Hammond [80], in
which the author highlights, in relation to a previous
study [81], how plasma lutein levels were unrelated
to cognitive enhancement in children. However, it is
worth noting that coarse cognitive assessments were
used.
The circulatory system delivers carotenoids to tar-
get tissue, and increasing concentrations of circulating
carotenoids have been shown to attenuate the adverse
effects of amyloid- peptide in human blood [82].
This peptide impairs red blood cells (RBCs) through
phospholipid peroxidation, thereby reducing oxygen
delivery to the brain, and a consequential increased
susceptibility to AD [82]. This attenuation of amyloid-
-induced RBC damage following treatment of RBCs
with xanthophylls, including L, is consistent with a
protective role for these carotenoids in terms of risk
for AD [82, 83].
We have confirmed previously observed positive
relationships between MP and serum concentrations
of its constituent carotenoids. Serum L concentrations
correlated significantly with all measures of MP in each
study group, whereas serum concentrations of Z cor-
related significantly with MP volume in each study
group, and these findings are consistent with previous
reports [27, 29, 78, 84, 85].
Taken together, the results of our study suggest
that MP levels may indeed be a reliable biomarker
of cognition in humans. Given that cognitive decline,
and diseases associated with cognitive decline, are
age-related and progressive (characteristics shared
with AMD), early intervention with formulations
containing the macular carotenoids, shown to be ben-
eficial in AMD, may offer some advantage in terms
of amelioration of the natural course of cognitive
decline associated with either aging or AD. Indeed a
recent study by our group has demonstrated that AD
patients, as well as normal control patients, respond to
carotenoid supplementation, in terms of MP augmen-
tation [35].
Several recent publications suggest health benefits
associated with long-term use of antioxidant sup-
plements, including L [58, 86, 87], and this should
be considered (in conjunction with other important
lifestyle variables) for healthy aging [77, 88, 89]. A
recent study, for example, suggests a dual strategy
for reducing risk for, and progression of, diseases
associated with cognitive decline, such as AD; a “pri-
mary prevention” approach refers to modification of
those risk factors amenable to intervention, in con-
junction with screening to identify preclinical disease
prior to damage mediated by amyloid plaque depo-
sition [90]. In a recent letter authored by a panel of
experts at the G8 dementia summit [91], governments
of those nations were encouraged to prioritize preven-
tion of dementia as a public health measure.
The limitations of this study include the L/Z
screener, which may be considered relatively crude,
the measurement of non-fasting patient serum sam-
ples for L and Z serum concentrations, the necessity
to simplify the cognitive variables VRM Trial 3 recall
and VRM Trial 3 intrusion errors into low and high
categories for analysis, and perhaps most significantly
the low correlation between results obtained from the
Densitometer and the Spectralis. This lack of correla-
tion is surprising as a previous report by our group
suggested that measures of MP obtained from the
Densitometer and Spectralis were highly correlated,
at least in subjects without ocular disease [92]. For
AMD subjects, concordance information is not cur-
rently available but is in fact under investigation by
our group. MP measurement has, however, previously
been extensively validated using the Densitometer [47,
93], including a study in AMD subjects [49]. An
absence of validation studies for physical MP mea-
surement methods such as fundus autofluorescence
measured by the Spectralis has been noted by other
groups [94], whereas the repeatability of the Densit-
ometer when using the customized heterochromatic
flicker photometry (cHFP) technique was confirmed
previously [95]. It is therefore our view that cHFP,
an optimized form of HFP, represents the best and
most dependable reference standard to which other
MP measuring techniques should be compared. Tak-
ing this into consideration, it is perhaps encouraging
that most of the correlations seen in our study in
relation to MP and cognition were with MP 0.25
(Table 3). This may be considered important as cen-
tral eccentricities were previously found to be those
where concordance was strongest between the Densit-
ometer and Spectralis, while agreements diminished
with increasing eccentricities [92]. Central MP would
thus perhaps be more likely to play a key role in con-
tributing to the correlations with cognition seen in this
study. It is also worth noting that while indeed absent
in general, there was one correlation evident between
MP volume and VRM (Fig. 2c). The cross sectional
design of the study may also be considered a possible
limitation.
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In conclusion, we have shown that MP levels cor-
relate with performance on a range of cognitive tests
in subjects free of retinal disease with low MP and
in subjects afflicted with AMD, and serum concen-
trations of MP’s constituent carotenoids were related
to verbal fluency (but this latter association was lost
when age, education and diet were controlled for).
Accordingly, it is reasonable to hypothesize that MP is
a valid biomarker for cognitive function, and its role in
this regard warrants further exploration for the wider
population. Finally, the possibility that supplementa-
tion with MP’s constituent carotenoids may delay the
onset or ameliorate the progression of cognitive decline
cannot be ignored.
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